

PHARMACY AND THERAPEUTICS (P&T) COMMITTEE

October 13, 2021

The meeting of the Pharmacy and Therapeutics (P&T) Committee of the North Carolina State Health Plan for Teachers and State Employees (the Plan) was called to order at 6:30 P.M. (EST) on Wednesday, October 13, 2021, via webinar, accessible to the public through the Plan's website. Quorum was not present.

MEMBERS PRESENT:

Jennifer Burch, PharmD, CDE, Owner, Central Compounding Center
Sundhar Ramalingam, MD, Oncologist, Duke Cancer Center
Peter Robie, MD, General Internist, Wake Forest Baptist Community Physicians
Phil Seats, RPh, Retired Pharmacist

MEMBERS ABSENT:

David Konanc, MD, Neurologist, Raleigh Neurology Associates
John Anderson, MD, MPH, Chief Medical Officer, Duke Primary Care
John J. Engemann, MD, Infectious Disease Specialist, Raleigh Infectious Disease Associates, PA
Joseph Shanahan, MD, Owner, Shanahan Rheumatology & Immunotherapy
Sheel Solomon, MD, Dermatologist, Preston Dermatology and Skin Surgery

PLAN & VENDOR STAFF:

Stephanie Craycroft-Andrews, PharmD, BCACP, Sr. Clinical Pharmacist, State Health Plan, Chairperson
Caroline Smart, Sr. Director, Plan Integration, State Health Plan
Dee Jones, Executive Director, State Health Plan
Sonya Dunn, MPA, BSPH, RN, Sr. Pharmacy Benefits Program Manager, State Health Plan
Renée Jarnigan, RPh, Clinical Advisor, CVS Health
Stephanie R. Morrison, PharmD, BCPS, Clinical Advisor, CVS Health

Welcome

The Chairperson welcomed the Committee members and guests to the webinar and performed roll call.

New Business

Dr. Robie requested a discussion regarding plan for coverage for the oral antiviral drug molnupiravir, as Merck submitted a request for Emergency Use Authorization (EUA) for the treatment of COVID-19 earlier this week. Ms. Smart explained that only COVID-19 vaccinations and testing, not pharmacological treatment, are covered at 100% of the patient cost share. Ms. Jarnigan explained that more information, including an NDC, are needed in order to generate a claim. There are a number of other steps including supply chain and distribution aspects that have yet to be determined. However, Ms. Jarnigan also assured the committee that, if EUA is granted, CVS will work with the Plan to determine the best way the new drug can be accessed in-between P&T Committee Meetings to meet the Plan's objective. Though it will not yet be on formulary, the drug may have a pathway for access through the New-To-Market Block exceptions process.

Adjourn



The Chairperson addressed the Committee by thanking them for their service and informed them that the meeting would be rescheduled. The meeting was adjourned at approximately 6:45 P.M. (EST).

Stephanie Craycroft-Andrews
Stephanie Craycroft-Andrews, Chair